Canine Cell-Based Flu Vaccines Should Have Patient Follow-Up, Cmte. Says
Executive Summary
Patient follow-up is needed for recipients of influenza vaccine produced using Madin Darby canine kidney cells, FDA's Vaccines & Related Biological Products Advisory Committee said
You may also be interested in...
Use of canine cells in flu vaccine development debated
The Vaccines and Related Biological Products Advisory Committee will discuss the use of Madin-Darby canine kidney cells in the manufacturing of live attenuated influenza virus vaccines. When the committee met in 2005 to discuss using the cells, it overwhelmingly agreed that companies should move forward with development, but also recommended that studies be done in animals inoculated with the final vaccine product (1"The Pink Sheet," Nov. 21, 2005, p. 22). It also recommended monitoring patients because of potential oncogenic risks from the tumorigenic canine cell lines
Use of canine cells in flu vaccine development debated
The Vaccines and Related Biological Products Advisory Committee will discuss the use of Madin-Darby canine kidney cells in the manufacturing of live attenuated influenza virus vaccines. When the committee met in 2005 to discuss using the cells, it overwhelmingly agreed that companies should move forward with development, but also recommended that studies be done in animals inoculated with the final vaccine product (1"The Pink Sheet," Nov. 21, 2005, p. 22). It also recommended monitoring patients because of potential oncogenic risks from the tumorigenic canine cell lines
Novartis’ New Vaccine Division Takes On Evolving Market
Novartis' newly acquired vaccines unit will face an increasingly differentiated market for flu vaccines, Vaccine & Diagnostic Business CEO Jörg Reinhardt said